You're viewing 1 of thousands of funding rounds tracked monthly
Members receive AI-scored leads and instant alerts when companies matching their criteria raise capital. Search all rounds by stage, amount, and investor.
Character Biosciences has secured $93 million in Series B funding to support two clinical trials for its treatments in dry age-related macular degeneration. The financing was co-led by new investors aMoon and Luma Group.
Character Biosciences has secured $93 million in Series B funding to support two clinical trials for its treatments in dry age-related macular degeneration. The financing was co-led by new investors aMoon and Luma Group.
03/25/25, 11:29 PM
Money raised
$93 million
Round Type
series b
Investors
Luma Group, A Moon
Character Biosciences is entering clinical trials with substantial company-generated human data to inform its treatments for dry age-related macular degeneration. The $93 million funding round will help achieve clinical proof of concept for its lead programs. The Series B financing, announced recently, was co-led by aMoon and Luma Group. Based in Jersey City, New Jersey, Character aims to address a significant patient population affected by AMD.
Company Info
Company
Character Biosciences
Test Drive Fundz
Try Fundz Free — See How Real-Time Signal Intelligence Feels
Explore our full lead generation platform. No credit card. No pressure — just the fastest way to discover how Fundz can help you close smarter.
Discover your first AI-ranked leads — tailored to your ICP
Use advanced filters to find promising companies
Save favorites, add notes, and preview company profilesNo credit card required. Upgrade anytime.
Free plan lets you:
- Run up to 5 filtered searches per day
- View up to 20 results per search
- Explore lead scoring & tracking tools
- Save notes and favorite companies
Trusted by teams at Google, Oracle, LinkedIn